✦ LIBER ✦

36 ORAL A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours

✍ Scribed by P. Schöffski; A. Awada; H. Dumez; T. Gil; S. Bartholomeus; J. Selleslach; M. Taton; H. Fritsch; N. Peter; G. Munzert

Book ID: 119599191
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 75 KB
Volume: 6
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(08)71968-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I, dose-escalation study of the

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

✍ Patrick Schöffski; Ahmad Awada; Herlinde Dumez; Thierry Gil; Sylvie Bartholomeus 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 245 KB

Phase I dose escalation study of MK-0457

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

✍ Anne M. Traynor; Maureen Hewitt; Glenn Liu; Keith T. Flaherty; Jason Clark; Stev 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 252 KB

1245 POSTER Phase I Dose-escalation Stud

1245 POSTER Phase I Dose-escalation Study of the Oral Selective C-Met Inhibitor EMD 1204831 in Patients With Advanced Solid Tumours

✍ G.S. Falchook; S. Fu; H.M. Amin; A.M. Tsimberdiou; D.S. Hong; A. Naing; M.B. Kle 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Phase I Study of GSK461364, a Specific a

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

✍ Olmos, D.; Barker, D.; Sharma, R.; Brunetto, A. T.; Yap, T. A.; Taegtmeyer, A. B 📂 Article 📅 2011 🏛 American Association for Cancer Research 🌐 English ⚖ 988 KB

1246 POSTER A Phase I Dose-escalation St

1246 POSTER A Phase I Dose-escalation Study of EMD 1214063, an Oral Selective C-Met Inhibitor, in Patients With Advanced Solid Tumours

✍ G.S. Falchook; S. Fu; H.M. Amin; S.A. Piha-Paul; D.S. Hong; A. Naing; M.B. Kleve 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

496 A phase I dose-escalation study of B

496 A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15 every four weeks, in patients with advanced solid tumours

✍ M. Scheulen; K. Mross; H. Richly; B. Nokay; A. Frost; D. Scharr; K.H. Lee; O. Sa 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 64 KB